Radiotherapy (RT) is a well established modality for treating many forms of cancer.
tion dose is often too low for tumor cure, because of the risk of normal tissue damage. Gene therapy provides a new adjunctive strategy to enhance the effectiveness of RT, offering the potential for preferential killing of cancer cells and sparing of normal tissues. This specificity can be achieved at several levels including restricted vector delivery, transcriptional targeting and specificity of the transgene product. This review will focus on those gene therapy strategies that are currently being evaluated in combination with RT, including the use of radiation sensitive promoters to control the timing and location of gene expression specifically within tumors. Therapeutic transgenes chosen for their radiosensitizing properties will also be reviewed, these include:
• gene correction therapy, in which normal copies of genes responsible for radiation-induced apoptosis are transfected to compensate for the deletions or mutated variants in tumor cells (p53 is the most widely studied example).
• enzymes that synergize the radiation effect, by generation of a toxic species from endogenous precursors (e.g., inducible nitric oxide synthase) or by activation of non toxic prodrugs to toxic species (e.g., herpes simplex virus thymidine kinase/ganciclovir) within the target tissue.
• conditionally replicating oncolytic adenoviruses that synergize the radiation effect.
Introduction
Radiotherapy (RT) is the use of ionizing radiation to destroy malignant tumors. It can be delivered either externally by X-rays and γ-rays or internally with the use of radioisotopes and remains one of the main strategies for treating almost all forms of solid tumors. This treatment can be highly effective for tumor eradication; for example the cure rate with RT for early cancer of the larynx is over 90% (1). In addition RT can be used palliatively to reduce or eliminate pain from bone metastases in 80% of patients (2). Although higher doses of radiation can produce better tumor control, the dosage that can be given is limited by the possibility of normal tissue damage within the radiation field, which can severely affect quality of life.
Several approaches are now being utilized to help improve local tumor control without compromising normal tissues. Recent advances in diagnostic imaging have lead to the development of conformal RT. This approach uses computed tomography and magnetic resonance imaging for more accurate treatment planning, allowing increased doses to the tumor with minimal late toxicity. Furthermore, intensity modulated radiotherapy (IMRT), the most advanced form of conformal RT, produces a non-uniform dose distribution across several radiation beams which summate to produce an optimum dose distribution conforming closely to the shape of the target tumor volume. Other approaches involve more frequent or accelerated fractionation schedules resulting in a significant improvement in local tumor control and a trend for better long term survival (3) (4) (5) .
Combination therapies are also proving useful.
Chemotherapy with RT has also been shown to enhance survival rates (6, 7) . In addition, the development of molecular targeted agents, including agents that act to override cancer specific pathways, such as modulators of apoptosis, inhibitors of intracellular signalling pathways, and cell cycle checkpoints are now being tested in combination with RT to modify the radiation response and to overcome radiation resistance (8) . In recent years, and the main focus of this review, the innovative marriage of radiation with gene therapy, termed radiogenic therapy, has been used to enhance anti-tumor efficacy. Research has shown that while many of these gene therapy approaches are unlikely to proceed on their own, combination with radiation can increase radiocurability.
Cancer Gene Therapy
Cancer gene therapy is the transfer of exogenous genes, called transgenes, into the somatic cells of a patient to obtain a therapeutic effect, possibly by inducing or suppressing a specific genetic function. In theory, gene therapy offers the potential for enormous improvements in the targeting of cancer therapy. However, it is equally clear that this has not yet been achieved, though there are some promising early trials. Cancers arise because of multiple genetic defects so it was always going to be a tall order to eradicate existing tumors by correcting these defects in all cancer cells in a patient's body. A more realistic approach, with current technology, is to use gene therapy as a means of generating high concentrations of an effector protein. This is likely to be an enzyme, which acts in a number of ways: to alter cellular pathways affecting sensitivity to chemotherapy or RT or to catalyze the production of toxic species, either from endogenous substrates or from administered prodrugs. Several cancer gene therapy approaches are currently in various stages of evaluation. These include genetic correction (or replacement) therapy whereby a faulty tumor suppressor gene is replaced or high oncogene expression levels are repressed with the use of antisense or siRNA technology; suicide gene therapy employs the use of genes that will lead to the generation of a toxic species, either directly or indirectly; gene directed enzyme prodrug therapy (GDEPT); anti-angiogenic therapy; and gene-based immunotherapy. All of these approaches have shown efficacy in preclinical studies, both in vitro and in vivo and many are now in clinical trial [for reviews in this area see (9) (10) (11) (12) ]. This review will focus on several key areas in which gene therapy has been combined with radiation to improve treatment outcome.
Replacement of Tumor Suppressor Genes to Increase Radiation-induced Apoptosis
Apoptosis is controlled both positively and negatively by multiple genes, many of which are mutated in human cancers.
Since these genes and their role in the apoptotic process are mostly well characterized, it is possible to employ rationale gene correction therapeutic approaches. Furthermore, since apoptosis is recognized as a fundamental mechanism of cell destruction in response to ionizing radiation, combined radiation and gene replacement strategies to increase apoptosis, specifically within tumors is a promising approach.
One of the genes most widely used in this combination strategy is the tumor suppressor, p53. Mutations in p53 result in impaired cellular response to DNA damage, genetic instability and they prevent apoptotic responses to radiation (13). Wild-type p53 (wtp53) gene replacement therapy has received great interest, especially since the prevalence of mutations in p53 is >50% in human tumors. Intratumoral injections of wtp53 using viral constructs results in tumor regression and apoptosis in a wide variety of tumor xenograft models [for a review see (14, 15) ]. As a result clinical studies exploring efficacy of wtp53 are now underway and are showing promising results (16); 30 clinical trials are listed within the USA, 5 trials within the UK, and 54 worldwide (17).
Several reports have indicated that the combination of RT and wtp53 gene therapy has synergistic suppressive effects on the growth of various cancer cell lines including colorectal (18), ovarian (19), nasopharyngeal (20), head and neck (21), and squamous cell carcinomas (22, 23); most have shown an increase in apoptosis when these two agents were combined. Furthermore, a phase II study in lung cancer patients showed that adenoviral (Ad) delivery of p53 (Ad-p53) in combination with radiation was well tolerated and demonstrated evidence of regression of the primary injected tumor (24, 25) . Interestingly, a marked increase in the apoptotic related genes, p21 WAF-1 , Mdm2, and in particular, BAK was observed in patient biopsies. The authors suggest that these markers may be useful for identifying patients likely to respond to Ad-p53 gene transfer. Other clinical trials involving the combination with p53 gene therapy with radiation can be seen in Table I .
Although p53 gene therapy is showing promise, some cancer models (in vitro and in vivo) are resistant to p53. However, Ad-mediated transfer of the p53 family genes, p73 and p51/p63 induces cell cycle arrest and apoptosis in colorectal cancer cells; this occurs, both in cells resistant to p53-mediated apoptosis and in two cell lines containing wtp53 (26). In SW480 cells, which are normally resistant to apoptosis, transduction of p51A/p63gamma combined with adriamycin or X-radiation induced extensive apoptosis. Transduction of p73beta and p51A/p63gamma also reduced the tumorigenicity of two colorectal cancer cell lines in vivo. These results suggest that Ad-mediated p73beta and p51A/p63gamma transfer are potential novel approaches for the treatment of human cancers, particularly for tumors that are resistant to p53 gene therapy. An alternative approach to target resistant tumors is to use, CTS1, an artificial p53based gene designed to resist various pathways of p53 inactivation. Ad-CTS1 induced growth arrest and loss of viability in a range of glioma cell lines. Ad-CTS1 also synergized with RT by inducing an unusual type of cell death that appears to be independent of BCL-2 family proteins, cytochrome c release, and caspases (27).
Other attractive candidates that can induce apoptosis in cancer cells include p16INK4 (28), p14ARF (29), and the E2F-1 trancription factor (30, 31), all of which show evidence of mutation in human tumors, and can induce apoptosis in a p53 independent manner.
Abnormalities in the p16 cell cycle inhibitory gene are potentially critical in the development of nasopharyngeal carcinoma (NPC). Its expression is silenced through either deletion or promoter methylation in the vast majority of NPC. Ad mediated p16 gene therapy (Ad.p16) decreased cell viability in a dose-dependent manner, down to 20% using 50 pfu/cell of ad.p16. The addition of RT administered 24 hr post-infection achieved only a slightly additive cytotoxicity (32).
Another promising candidate for gene replacement therapy is the melanoma differentiation associated gene-7 (mda-7/IL-24) which exhibits cancer cell specific growth inhibitory properties when expressed at supra-physiological levels and can induce apoptosis. In vivo experiments show that Admda-7 inhibits tumor growth and induces apoptosis in xenograft models of breast (33), melanoma (34), ovarian (35), pancreatic (36), and lung cancer (37). Combination of this gene with radiation demonstrates increased efficacy; Admda-7 enhanced the radiosensitivity of non-small-cell lung cancer (NSCLC) cells independent of their p53 gene status while normal lung fibroblasts seemed to be relatively resistant to the cytotoxic effects of Ad-mda-7 compared with the NSCLC cells and were not radiosensitized. In addition, an enhancement of radiation-induced apoptosis was also evident in Ad-mda-7 transduced cells (38, 39) . A Phase II trial is now recruiting in which this gene is combined with RT in patients with locally recurrent breast cancer (see Table I ).
The human TESTIN (TES) gene is a putative tumor suppressor gene. Ad-TES expression has been shown recently to inhibit the growth of breast and uterine cancer cells lacking TES expression through caspase-dependent and caspaseindependent apoptosis (40). Another tumor suppressor gene, TSLC1, is silenced in a number of human tumors and cell lines, including lung, prostate, liver, stomach, pancreatic, and breast tumors. Ad delivery of TSLC1 inhibited cell proliferation and induced apoptosis in the non-small-cell lung carcinoma (NSCLC) cell line A549 and inhibited A549 tumor growth in nude mice by 70-80% (41). Both of these strategies are yet to be tested in combination with radiation, but represent promising new candidates.
The Use of Apoptosis-inducing Transgenes in Combination with Radiation
Numerous other genes that have been characterized for their role in apoptotic pathways, other than the classical tumor suppressors mentioned in the previous section, are also being utilized in gene therapy strategies, some in combination with RT. They include Caspase 1, 3, 8, and 9 (42-45), Fas-ligand (46), a potent proapoptotic Bcl-2 family member, BimS (47), CD95L (48), TRAIL (49), and Bax (see later). Alternatively, anti-apoptotic proteins such as Bcl-2 (50), Bcl-X L (51), XIAP, and survivin (52) have been downregulated by antisense, ribozymes, or siRNAs. Those that have been thoroughly tested in combination with radiation will now be discussed.
Exogenous Bax-mediated induction of apoptosis sensitizes breast cancer (53, 54), ovarian cancer (55), esophageal cancer (56), and glioma (57) to radiation. In the latter, combined treatment also induced marked regression of malignant gliomas in mice. Bax was discovered through its ability to bind to the bcl-2 protein, and was soon shown to counter its death-suppressing activity. Interestingly, Bax itself does not cause cell death; in fact, its proapoptotic effect is exerted only after a concomitant death signal, such as deprivation of a growth factor, or RT (58).
Most malignant astrocytomas (gliomas) express a high level of Fas, whereas the surrounding normal neurons and astrocytes express very low levels. Thus, transduction of Fas ligand would selectively kill malignant astrocytoma cells. Furthermore, glioma cells are resistant to conventional therapies including radiation. An Ad linked to Fas (Ad-FL) has been used to infect U-373MG glioma cells in combination with radiation; this lead to an 81% increase in apoptosis as compared to Ad-FL treatment alone. There was a marked reduction in the caspase-3 level and an increase in the cleaved form of poly(ADP-ribose) poly-merase (PARP), which are downstream components of Fas ligand-mediated apoptotic pathways (46).
The proapoptotic effect of an Ad expressing caspase-8 in DLD-1 colon cancer cells in combination with radiation has also been assessed. Under these conditions, X-irradiation strongly induced apoptosis whereas irradiation without transduction had only a weak proapoptotic effect (44). hTERT/rev-caspase-6 exhibited a greater ability to induce apoptosis in malignant glioma U87-MG and U373-MG cells than hTERT/caspase-8, but the effect of caspase 6 was not enhanced by radiation (59).
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/Apo2L) is of particular interest in the development of prostate carcinoma therapeutics as it preferentially induces apoptosis of tumor cells. The combination of ionizing radiation and Ad-driven TRAIL expression overcame human prostate cancer cell resistance to TRAIL. Furthermore, in vivo administration of AdFlt-TRAIL at the site of tumor growth in combination with radiation treatment produced significant suppression of the growth of DU145 human prostate tumor xenografts in athymic nude mice. Results suggest that specific TRAIL delivery employing the FLT1 promoter can effectively inhibit tumor growth and demonstrate the advantage of combination RT and gene therapy for the treatment of prostate cancer (49).
Other Radiosensitizing Transgenes
There are a host of other interesting transgenes which aid in the sensitization of tumors to RT. These genes have wide ranging functions, such as direct radiosensitization, inhibition of DNA repair, anti-angiogenesis, regulation of growth factor receptors, and upregulation of anti-tumor immunity. All of these genes showing synergy with radiation have been listed in Table II . Perhaps the most well studied of these genes, with numerous anti-cancer properties are tumor necrosis factor-α (TNF-α) and inducible nitric oxide synthase (iNOS).
TNF-α is attractive as a therapeutic protein since it is secreted and has a broad range of potent anti-cancer properties. These include, activation and recruitment of immune cells, induction of tumor necrosis by disruption of the tumor vasculature and induction of free radicals leading to tumor cell kill via DNA strand breakage, and apoptosis. Combining TNF-α gene therapy with radiation in a range of tumor cell lines showed greater anti-tumor efficacy than either modality alone (60, 61). Furthermore, increased efficacy was observed when proton radiation was used instead of γ-rays (62-64).
Weischselbaum and colleagues pioneered the combination of driving TNF-α with radiation inducible CArG elements from the EGR-1 gene as a new anti-cancer therapy with increased targeting specificity to overcome systemic effects (60). This combination has produced striking anti-tumor effects in animal models. Preclinical and early phase I trials indicated that effective concentrations of Ad.EGR-TNF-α (TNFerade) could be delivered to the tumor site without significant systemic effects. Furthermore, potent anti-cancer activity has been observed with a high rate of complete and partial objective tumor responses (65, 66). TNFerade is now in phase II/III clinical trials (see Table I ).
Inducible nitric oxide synthase, an enzyme which generates nitric oxide (NO • ) is another potent therapeutic transgene with numerous anti-cancer properties including cytotoxicity, radiosensitization, and anti-angiogenesis, making it an attractive molecule for use in cancer gene therapy. NO • was first shown to be a radiosensitizer in bacteria and mammalian cells over 40 years ago (67), but it was not until the last decade that the potential importance of this property was recognized. Studies showed that concentrations of NO • donor drugs, in the mM range, gave sensitizer enhancement ratios of 2.1-2.5; this is almost as efficient as oxygen and much more efficient than any radiosensitizing drugs that have been tested in vivo (68, 69). The precise mechanism/s by which NO • radiosensitization occurs is not fully understood. NO • is not known to interact directly with biological molecules although a number of reactions are theoretically possible. NO • has, however, been shown to cause thiol (particularly GSH) depletion and this could lead to radiosensitization at intermediate oxygen concentrations (Wardman and Dennis, personal communication). We were the first group to demonstrate that iNOS gene therapy could increase the sensitivity of hypoxic tumor cells to radiation (70). We showed that iNOS gene therapy effectively eliminated the tumor cell radioresistance observed under hypoxic conditions. This strategy was confirmed in vivo; a dramatic growth delay, probably apoptosis related, was observed following direct intratumoral injection of iNOS, compared with controls receiving radiation alone (71, 72). Other groups have shown similar effects (73-75).
The Use of Prodrug Metabolizing Genes to Enhance Chemo-Radiotherapy
GDEPT is a two-step strategy where a gene encoding a drug metabolizing enzyme is delivered to a tumor, followed by administration of a non-toxic prodrug that is activated to a potent cytotoxin by the expressed enzyme. The aim of GDEPT is to increase enzyme levels specifically within the tumor; this should promote increased production of the cytotoxin and hence tumor-specific cell kill, while minimizing damage to the surrounding normal tissue. Since the dose of standard chemotherapy agents required to achieve a sufficient anti-tumor effect often results in severe systemic toxicity, GDEPT can be used to improve the therapeutic ratio by reducing the dose required for an equivalent level of efficacy.
The success of GDEPT strategies is normally improved if a bystander effect is present. This occurs when the generated cytotoxin is capable of diffusing into neighboring non-transfected tumor cells increasing overall cell kill (76, 77) . This advantage is of particular importance since, with all gene therapy strategies, inefficient transfection can compromise therapeutic success. When a bystander effect occurs it should be necessary to transfect only a fraction of the tumor cells to provide complete tumor eradication.
Two recent reviews have discussed prodrug development (78) and the range of enzyme/prodrug combinations available for effective GDEPT combinations (79). Many GDEPT studies have shown a good to excellent anti-tumor effect in cells and animal models but translation to the clinic is more problematic. In most of the clinical trials reported, gene delivery has been achieved by direct injection into the tumor of herpes simplex virus type-1 thymidine kinase (HSV-TK) combined with the anti-viral drug ganciclovir (GCV). Most have shown the safety of the approach, but there has only been a limited tumor response to the protocols. The poor efficacy is partly explained by the preponderance of Phase 1 trials among those that have reported.
A number of studies have reported the use of GDEPT in combination with radiation. As with other GDEPT strategies in vitro and in vivo studies have been promising, however, translation to the clinic is slow. Currently there are 8 trials recruiting (and one closed) where radiation and gene therapy are being combined (Table I) . The most widely studied radiation -GDEPT combinations also involve HSV-TK/GCV. The active cytotoxin inhibits DNA polymerase and becomes incorporated into DNA, resulting in cell kill in rapidly proliferating cells (80). Combination of this system with Xirradiation results in enhancement of cytotoxicity both in vitro (81) and in vivo (82). More recently, multiple treatments of HSV-TK/GCV gene therapy in combination with radiation resulted in an enhanced therapeutic effect in a mouse mammary tumor model (83). Using an Ad delivery system, Kanazawa et al. (84) showed tumor regression in a head and neck tumor xenograft model using HSV-TK in combination with radiation. When the radiation-inducible CArG promoter (see more detailed discussion later) was used to drive HSV-TK expression in MCF-7 cells a 30% greater cell kill was demonstrated in a GDEPT plus radiation strategy compared to radiation alone (85).
Another GDEPT strategy that has been widely investigated is the combination of cytosine deaminase (CD) with the antifungal agent 5-fluorocytosine (5-FC). CD converts 5-FC to the commonly used chemotherapy agent 5-fluorouracil (5-FU), which causes cytotoxicity through a number of mechanisms. Synergistic effects have been demonstrated by combining CD/5-FC GDEPT with radiation in vitro (86) and in vivo (87). In a LNCaP prostate xenograft model, CD/5-FC in combination with a low radiation dose (1Gy) resulted in a significant anti-tumor effect (28). When human bladder cancer cells were treated with a combination of an Ad delivered CD/5-FC system and radiation, enhanced cell kill was observed regardless of the p53-status (88). Co-transduction with cDNA encoding phosphoribosyltransferase (UPRT), an enzyme that is required for conversion of 5-FU to 5-FUMP can significantly enhance the anti-tumor effects of CD/5FC (89). In a GDEPT study combining radiation with CD/5-FC and UPRT, a significant cytotoxic interaction was observed in glioma cells, however in vivo, adverse effects were observed in normal brain (90). Further optimization of the radiation dose/field size may allow this approach to become a feasible treatment option for gliomas.
A novel chimeric fusion gene, E.coliCDglyTK, combining bacterial CD and HSV-TK has been evaluated (91). It enhanced the toxicity of 5-FC and GCV and sensitized cells in vitro when combined with radiation. Other investigators have confirmed these results (84, 92). Lee et al. (93) found that exposing CDglyTK transduced cells to hyperthermia (41°C for 4 h) elevated the level of transgene expression by 5-20 fold with a corresponding enhancement of cytotoxicity and radiosensitivity. In the CNE-2 nasopharyngeal carcinoma xenograft model, a yeast CD and HSV-TK fusion gene was combined with radiation and prodrugs, resulting in a 91% cell kill in vitro and a significant anti-tumor effect in vivo (94).
Metabolism of indole acetic acid (IAA) by horseradish peroxidase (HRP) produces a wide range of cytotoxic species, including superoxide and peroxyl radicals (95). When this approach was combined with X-rays in T24 bladder or FaDU nasopharyngeal carcinoma cells a significant enhancement of cytotoxicity was observed. Radiosensitization was also observed if prodrug exposure was performed immediately after irradiation or in anoxic conditions (96).
Bioreductive drugs are a class of prodrugs that offer additional tumor specificity since they are metabolized only in hypoxic cells, which are frequently found in tumors but rarely in normal tissue (97, 98) . Hypoxia is known to be a cause of both treatment resistance (99) and malignant progression (100). Consequently, targeting of these cells in combination with a modality such as radiation, which is more effective against the well-oxygenated cells, is an attractive approach for improvement of tumor control. The most extensively studied gene/bioreductive combinations involve AQ4N (1,4-bis[[2-(diamethylamino-N-oxide)ethyl]amino]-5,8-dihydroxy-anthracene-9,10-dione) and tirapazamine.
AQ4N is a non-toxic bioreductive prodrug that, in the absence of oxygen, is reduced to AQ4, a mitoxantrone analogue. AQ4 causes cytotoxicity by non-covalent binding to DNA, and exhibits a bystander effect that does not require cell-to-cell contact (our unpublished data). It is metabolically stable, exerting its effect for many days, and can be used to complement both RT and chemotherapy regimens (101-104). Despite good anti-tumor efficacy being observed using a non-GDEPT strategy, further cytotoxic effects could be achieved in vivo by combining CYP3A4 or CYP2B6 and AQ4N with radiation treatment (105, 106).
Cytochrome P450 reductase (CYPRED) metabolizes various bioreductive drugs, including tirapazamine. Using a hypoxia-responsive element (HRE) to selectively express CYPRED only within hypoxic areas in the tumor mass, Cowen et al. (107) observed complete regression in 5 out of 6 tumors treated with tirapazamine and 10 Gy radiation. GDEPT strategies involving CYPRED have also been shown to increase sensitivity to other chemotherapy agents including mitomycin C (108) and cyclophosphamide (109).
Clinical Trials Utilizing GDEPT Strategies in Combination with RT
There are currently eight clinical trials recruiting that involve GDEPT combined with conventional RT; one has already closed. All of these trials involve HSV-TK/GCV and the majority are in patients with brain tumors, who have limited treatment options (Table I ). In early studies retrovirus-producing cells (RPCs) that express HSV-TK were injected directly into glioblastomas. In a Phase III trial using this approach, 248 patients were treated with either standard therapy (RT or surgical resection) or GDEPT and standard therapy (110). GDEPT did not improve time to tumor progression or survival time, although the treatment was safe. In patients with prostate cancer, combination of radiation with AdHSV-TK and valaciclover (a GCV analogue) was also reported as safe (111). Loco-regional control was reported, however systemic control was inadequate (112).
Clearly the use of GDEPT to complement conventional RT is highly promising in a pre-clinical situation. A wide range of combinations can enhance tumor control, however gene delivery and scheduling of gene/drug/radiation provide considerable hurdles to identification of effective regimens capable of improving tumor control in patients.
Replicating Viruses in Combination with Radiation
Oncolytic virotherapy is the use of genetically engineered viruses that specifically target and destroy tumor cells via their cytolytic replication cycle. Viral-mediated tumor destruction is propagated through infection of nearby tumor cells by the newly released progeny. Much of the work to date involves the use of adenoviruses and herpesviruses (113, 114) , which can also function as therapeutic gene delivery vehicles.
Radiation-induced cell death is dependent on damaging DNA either directly or indirectly through the formation of oxygen radicals that disrupt cellular pathways; an entirely different mechanism of cell kill from that of replicating viruses. This has led to several preclinical trials looking at the role of combining these two modalities, since attacking tumors by two different mechanisms should reduce tumor cell resistance. Intra-arterial injections of dl1520 (also known as ONYX-015, containing a deletion in E1B-55kD protein) in conjunction with total body irradiation (5 Gy) were evaluated in malignant glioma and colon xenograft models that were either p53 mutant or p53 wild-type (115). Significant tumor growth delays were noted in the p53 mutant tumors receiving combination therapy versus monotherapies (116).
An EBV-dependent transcriptional targeting strategy was used to construct a novel conditionally replicating Ad, ad.oriP.E1A. Its combination with radiation caused complete disappearance of established tumors for at least 2 weeks in two distinct EBVpositive nasopharyngeal carcinoma xenograft models (117).
Other adenovirus type 5 (Ad5)-based replication-competent cancer gene therapy vectors include KD1, KD3, and VRX-007. All three vectors overexpress an Ad5 protein named Adenovirus Death Protein (ADP, also named E3-11.6 K protein). ADP is required for efficient lysis of Ad5-infected cells and spread of virus from cell to cell, and thus its overexpression increases the oncolytic activity of the vectors. Furthermore, KD1 and KD3 contain mutations in the Ad5 E1A gene that knock out binding of the E1A proteins to cellular p300/CBP and pRB; these mutations allow KD1 and KD3 to grow well in cancer cells, but not in normal cells (VRX-007 has wild-type E1A). In combination with radiation all three vectors demonstrated an increase in oncolytic activity, that was not related to radiation-induced replication of the vectors. The combination of radiation plus KD3 suppressed the growth of A549 lung adenocarcinoma xenografts in nude mice more efficiently than radiation alone or KD3 alone (118). Enhanced anti-tumor efficacy was also observed in radiation combination studies with Ad5-Delta24RGD (119) and CV706 (120).
G207 is an oncolytic herpes simplex virus (HSV) with deletions at both gamma134.5 loci and a LacZ gene insertion inactivating the HSV ribonucleotide reductase gene. The combination of G207 with radiation treatment generated more than additive effects in head and neck cancer cell lines both in vitro and in vivo; even the radiation-resistant cell lines (SCC25, MSKQLL2, SCCVII) were susceptible (121). These promising preclinical studies have provided evidence for the initiation of a number of clinical trials (Table I) . Therapeutic genes, such as those coding for prodrug activating genes, have also been used in combination with oncolytic viruses (122-125).
Radiation-induced Transcriptional Targeting of Therapeutic Transgenes
Gene therapy offers the potential for tumor targeting specificity at several levels. Of these, transcriptional targeting has been a major focus of recent research (126). Promoters specific to the target tissue or to characteristics of tumor growth and progression have received much attention, as have those regulated by hypoxia. These approaches are attractive because they are capable of targeting both primary tumors and small metastatic deposits. The use of promoters that are responsive to radiation doses in the clinical range offers the opportunity to exploit the targeting precision now possible with IMRT in the volume-specific regulation of therapeutic transgenes; their enzyme products can thus generate cytotoxic or radiosensitizing molecules predominantly within the target cells, allowing much higher tumor:normal tissue ratios to be achieved than with systemic administration of cytotoxic agents.
Radiation-inducible Promoters
It has been known for many years that, in addition to causing cell death, ionizing radiation causes changes in gene transcription and protein expression (127). However, it was not until the early 1990s that the inducibility of specific genes by radiation was thoroughly investigated.
One of the first radiation-inducible promoters to be identified was tissue plasminogen activator (t-PA), which activates plasminogen to the active protease plasmin and is implicated in processes that involve extracellular proteolysis (128). Boothman et al. (129) were the first to demonstrate induction of t-PA in human tumor cells by X-rays as well as by UV radiation and phorbol ester exposure. mRNA expression was increased up to 100 fold by low doses of X-rays. Following characterization of the X-ray-responsive element (XRE) in the t-PA promoter it was proposed as a likely candidate to drive therapeutic transgenes for use in cancer therapy (130), however, we are not aware that any protocols using this promoter have been tested. The mechanisms responsible for its regulation by X-rays are not well understood though there is now evidence that reactive oxygen species and inflammatory cytokines may be involved (131). Several other promoters have been developed for use in cancer gene therapy and these will now be discussed.
Early Growth Response Gene (EGR-1)
Early investigations of X-ray inducible genes identified the early growth response gene EGR-1 as a promising promoter for gene therapy. It encodes a transcription factor that binds specifically to the GCGGGGGCG consensus sequence identified in the promoters of many regulatory cytokines including bFGF, IL-1, PDGF-α, and TNF-α. Like many immediate early genes it is responsive to a wide range of noxious stimuli from hypoxia to shear stress (132). Again, reactive oxygen intermediates are implicated in signal transduction because its response to activation by H 2 O 2 can be abrogated by n-acetly-L-cysteine (133). The EGR-I promoter and its radiation responsive elements have since been extensively tested and developed for use in cancer gene therapy protocols. The first studies were conducted using human leukemia cells stably transfected with CArG [CC(A+Trich)6GG] elements from the EGR-1 promoter driving the TNF-α gene. Induction of TNF-α was observed when cells were exposed to radiation doses in the clinical range. When the transfected cells were injected directly into human carcinoma xenografts TNF-α protein was generated in response to X-rays and an increased anti-tumor effect was observed using tumor cure as the endpoint (60). This study was used to inform a viral vector-mediated gene therapy approach (Ad.EGR-1-TNF-α) again using direct tumor injection; it achieved marked tumor radiosensitization in the absence of any normal tissue toxicity (134). This approach has since been developed by that group as "TNFerade", a gene therapy using intra-tumoral injection for the treatment of human cancer. A phase I study in a range of advanced, treatment refractory solid tumors showed that the therapy was well tolerated in combination with a palliative RT regime to exploit synergy between the two modalities and in addition some promising responses were noted (135) ( Table I) . Radiation inducibility and low basal level activity are key attributes for a promoter in a therapeutic setting. To improve on the performance of the EGR-1 promoter, synthetic promoters have been constructed from tandem repeats of CArG sequences and extensive optimization experiments conducted. These revealed that the optimum radiation inducibility at clinically relevant radiation doses (∼2 Gy) was achieved when 9 CArG elements were incorporated (136). An additional sophistication is the use of "chimeric" promoters that incorporate desirable characteristics of more than one promoter into a single construct. The addition of the cytomegalovirus immediate early basal promoter (CMV IE) has been tested with some success to achieve the characteristics of a strong, normally constitutive, promoter together with the radiation inducibility of the CArG elements (137). An alternative and rather appealing strategy was also tested by this group: CArG elements were combined in a chimeric promoter with elements conferring inducibility by hypoxia. Of these, the erythropoietin (EPO) promoter showed the highest induction (138). Furthermore, the Epo/CArG promoter showed inducibility at oxygen tensions typically found in human tumors (139). To our knowledge this promising combination has not yet been tested in vivo. However, our own studies have shown that the 9 CArG element promoter (pE9) can be used effectively in vivo to drive a therapeutic transgene (inducible nitric oxide synthase) in a suicide gene therapy strategy, even in the absence of radiation (72). Using only a single intratumoral injection of 25µg of DNA in a lipid vector, growth inhibition of a mouse sarcoma was greater than that achieved with a single 20 Gy dose of X-rays. The pE9/iNOS gene therapy was accompanied by a 4 fold increase in iNOS protein levels and an 8 fold increase in its enzyme product, nitric oxide (NO • , measured as nitrite) in the tumors. We also showed that the pE9 promoter is inducible by NO • , because a specific, competitive inhibitor of NO • synthesis prevented promoter activation. It is likely that transduction of this effect is via the same mechanism through which reactive oxygen products of irradiation activate the CArG elements. These characteristics make the pE9/iNOS combination highly attractive for gene therapy of cancer and possibly also other tissues such as the vasculature.
The EGR-1 promoter in various forms has also been tested in combination with several other therapeutic transgenes. Cytochrome p450 (CYP) 4B1 under the control of the EGR-1 promoter was used to convert an inert prodrug, 4ipomeanol, into alkylating metabolites on exposure to radiation. Enhanced cytotoxicity was observed in vitro (140). EGR-1 driven gene therapy has also been used to stimulate anti-tumor immunity. Inhibition of tumor growth was observed when a plasmid (in a lipid vector) incorporating the EGR-1 promoter upstream of two genes (IL-18 and B7.1) that stimulate activation of T lymphocytes and natural killer cells, was injected into B16 mouse melanomas (141). Tumors were irradiated with 2 or 5 Gy X-rays at 1, 3, and 5 days after plasmid injection. Regrettably, full tumor regrowth was not followed, so growth delay data could not be calculated, but growth inhibition was clearly superior after the 5 Gy fractionated dosing plus gene therapy compared with radiation alone.
Another interleukin, oncostatin M (OSM), a member of the IL-6 family (142), has also been used as a therapeutic transgene in combination with EGR-1. A chimeric promoter, generated by insertion of hypoxia response elements (HREs) upstream of the EGR-1 promoter was used to drive OSM both in vitro and in a human lung cancer (A549) xenograft model in vivo. Impressive anti-tumor effects were observed when HRE-EGR-1/OSM gene therapy was combined with 6 Gy of X-irradiation (143). The same group also tested the chimeric promoter in combination with HSV-TK/GC and observed marked tumor regression in the same model (144).
Wild-type p53 Activated Fragment WAF1
WAF1, also known as p21 or CIP1 is a cyclin-dependent kinase inhibitor (145), suppressing cell growth. It has also been shown to be involved in the immediate early response to a variety of stresses (146). The promoter region has a p53 binding site, upstream of WAF1 coding sequences, that has been shown to confer p53-dependent inducibility upon the gene (147). There is also specific evidence that radiationinducibility in vitro occurs in a p53 dependent manner (148, 149) . However, p53-independent activation pathways are also known to exist (146, 150, 151) .
However, p53 status did not significantly impair the radiation inducibility of WAF1 in vivo (71). We have investigated the anti-tumor efficacy of intratumoral injection of a plasmid construct in which the WAF1 promoter was cloned upstream of the iNOS gene in tumors expressing either wildtype (RIF-1) or mutant (HT29) p53. A single injection, followed 16 h later by a promoter-inducing dose of 4 Gy, resulted in significant sensitization to a subsequent therapeutic dose of X-rays. In RIF-1 tumors the anti-tumor effect of 20 Gy alone was slightly less than that of 10 Gy X-rays plus the WAF1/iNOS gene therapy; this is consistent with an enhancement ration of ∼2.0. In HT29 tumors (mutant p53) the enhancement was slightly lower (∼1.6) and this could be attributed entirely to a lack of anti-tumor effect of the gene therapy alone in HT29 tumors, whereas in RIF1 tumors, gene therapy in the absence of any radiation was as effective as a single dose of 10 Gy X-rays alone. WAF1-mediated induction of iNOS was similar in both tumor types, so lack of tumor cell cytotoxicity in the p53 mutant HT29 cells could rather reflect the p53 dependency of NO • -mediated apoptosis induction (73, (152) (153) (154) . Thus, WAF1 can be an effective cancer gene therapy promoter, combining low basal activity in normal tissues (71) with impressive transgene activation in the irradiated volume.
Other Promoters
The promoters from many other stress response genes are potential cancer gene therapy candidates [see (155) for review]. Gadd45 (156), Rous sarcoma virus (157) and IL-6 (158) are also clearly induced by ionizing radiation, but their promoters have not yet been tested in gene therapy protocols. With the obvious exception of TNFerade (135) no cancer gene therapy incorporating radiation-inducible promoters has reached human trials even though clear efficacy has been demonstrated for several protocols in animal models.
Targeted RT by Overexpression of Membrane Transporters
The radio-targeted gene therapy approach to localizing radionuclides at tumor sites involves inducing tumor cells to synthesize a membrane-expressed transporter or receptor with a high affinity for an injected radiolabeled ligand. The cloning of the sodium iodide symporter (NIS) gene and the noradrenaline transporter (NAT) has made this approach a realistic proposition. NIS/NAT gene transfer is followed by the application of targeted RT in the form of the radionuclides ([ 131 I]iodine (Na 131 I) for NIS and [ 131 I]meta-iodobenzylguanidine ([ 131 I]MIBG) for NAT). NAT and NIS are responsible for the active uptake of [ 131 I]MIBG and Na 131 I respectively. There is considerable clinical experience in the use of [ 131 I]MIBG and Na 131 I in the treatment of neuroblastoma and thyroid carcinomas (159). However, overexpressing NIS and NAT in gene therapy based strategies has now allowed the possibility of targeting a wider range of tumor types [reviewed by (159-165) ]. Another similar strategy involves increasing expression of human somatostatin receptor subtype 2; when radiolabeled somatostatin analogues are administered a significant inhibition of growth was observed in a range of human tumor xenografts (166, 167) .
The use of gene transfer technology to induce expression of high-affinity membrane receptors or transporters can enhance both the specificity and extent of radio-ligand or radionuclide localization in tumors, sparing normal tissue damage. Furthermore, the use of radionuclides with appropriate emissions can deliver cytotoxic absorbed radiation doses across several cell diameters to compensate for limited transduction efficiency (168) . Clinical studies are needed to determine the most promising of these new therapeutic approaches.
Radioprotective Gene Therapy
RT alone or in conjunction with combination chemotherapy is often limited by normal tissue toxicity within the transit volume of RT beams. Radioprotective gene therapy, using transgenes coding for anti-oxidants that can ameliorate the effects of radiation-induced reactive oxygen species is now being used to spare normal tissues. The anti-oxidant manganese superoxide dismutase (MnSOD) has been delivered to specific target organs using gene transfer vectors including plasmid/liposomes (PL) and Ad (169). Application of MnSOD-PL gene therapy in the setting of fractionated chemo-RT is being tested in clinical trials for prevention of oesophagitis during treatment of non-small-cell carcinoma of the lung, and in prevention of mucositis during combination therapy of carcinomas of the head and neck (170). In a slightly different approach, the EGR-1 promoter was used to drive expression of a novel cytokine, Flt3 ligand (FL), which is involved in regulation of early hematopoiesis; this combination showed efficacy in protecting hematopoietic cells from radiation-induced damage (171).
Vectors and Their Limitations
Central to the concept of gene therapy is the efficient delivery of exogenous DNA to the target cells. The ideal vector should enter the target cell efficiently, remain stable while its expression is required therapeutically, should not produce pathogenic effects such as immunogenic and inflammatory responses or harmful integration and should be economical. However, in reality, viral and non-viral vectors, if systemically administered, are rapidly cleared from the circulation, limiting transfection to 'first pass' organs such as the liver, spleen, and lungs [for a review in this area see (172)]. So while all the exciting approaches combining radiation with gene therapy for a more effective cancer treatment forge ahead, development of more efficient delivery systems are urgently needed. A number of promising strategies are now being developed to target both viral and non-viral delivery agents to tumor cells. These include exploitation of natural viral tropisms, re-targeting viruses using a bispecific molecule to simultaneously block native receptor binding, redirecting virus to a tissue -specific receptor; genetically modifying the virus to ablate native receptor interactions and incorporating a novel ligand into one of the virus' coat proteins, using tissue specific ligands or monoclonal antibodies incorporated onto the surface of liposomes to direct them to target cells. A detailed description of these targeted delivery strategies, lies beyond the scope of this review [for a review in this area see (173)].
Conclusions
In this review we have evaluated the diverse gene therapy strategies that could be used to enhance the effectiveness of RT. This combined modality approach is entirely appropriate because RT, applied in an increasingly sophisticated manner, is likely to be an important cancer treatment modality for many years to come. In common with all forms of gene therapy, significant problems remain to be overcome if radiogenic therapy is to achieve wider application in the clinic. Promoter specificity is usually attained at the expense of the strength of transgene activation, although new approaches are being developed to overcome this (137). A further problem is the lack of effective systemic delivery systems; by their very nature the large molecules or viruses currently used for this purpose are likely to be intercepted by host defense systems before they reach the target tissue in adequate concentrations. Several imaginative approaches to this problem are currently being tested and it is probable they will be increasingly successful (173) (174) (175) (176) (177) . However, with current technology including ultrasound guidance if necessary, many primary tumors and secondary lymph nodes would be accessible to direct injection of gene therapy constructs in viral or lipid vectors. It is also likely that significant clinical benefit would be obtained in some patients, with less morbidity than accompanies conventional drug therapy. The major impediment to further progress is the justifiably cautious approach adopted by regulatory authorities to human gene therapy and the profound mistrust by the public of any form of genetic manipulation. These attitudes have been hardened by a few tragic and well publicized deaths and cases of severe morbidity resulting from reactions to some gene therapy vectors. Nevertheless, it is possible to introduce new gene therapy concepts to the clinic within the evolving regulatory framework (178, 179) and the potential clinical benefits are likely to justify the effort involved. 
